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Abstract 
Extranodal nasal-type natural killer/T-cell lymphoma (NKTL) is a rare and aggressive form of 
lymphoma with a poor survival rate. A better understanding of the molecular mechanisms will 
aid our understanding and help the development of targeted drugs or drug combination that will 
improve patient survival rate. Our group previously showed that EZH2, a histone 
methyltransferase, is abnormally over-expressed and confers growth advantage to NK cells. To 
examine the functional importance of targeting Ezh2 in NKTL, we treated NKTL cells with 
DZNep, an inhibitor of Ezh2. We found that DZNep effectively induces apoptosis in NKTL 
cells, and the drug effects were executed through the specific inhibition of Ezh2. We further 
examine the underlying molecular mechanisms by which DZNep exert its effect on NKTL cells 
using gene expression profiling (GEP). We defined the mechanism by which DZNep induces 
apoptosis in the NKTL cells, through the de-repression of TNFAIP3/A20, a tumor suppressor 
gene. In cells with high Ezh2, TNFAIP3/A20 is silenced through the histone methyltransferase 
activity of Ezh2, resulting in an activation of NF-kB and an oncogenic effect. To conclude, we 
unravel the oncogenic pathway of Ezh2 in NKTL cells through regulation on TNFAIP3/A20 and 
NF-kB, and also demonstrated the possibility of targeting Ezh2 using DZNep in NKTL. 
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CHAPTER 1. INTRODUCTION 
 
1.1 Natural killer (NK) cells  
Natural killer (NK) cells are lymphocytes that belongs to the innate immune system, responsible 
for the first-line defense against infections and several diseases (1). They play an important role 
in preventing tumor formation as well as kill cells that were infected with viruses (e.g. herpes 
simplex virus-1). They are cytotoxic cells containing granules that are responsible for their 
effector activities. The granules, containing perforin and proteases, causes apoptosis of target 
cells when the granular contents are released. Therefore, NK cells have a sophisticated 
mechanism of differentiating diseased cells from healthy cells. NK cells became activated in 
response to presence of interferons, macrophage-derived cytokines, or interaction with other 
cells of the immune system (e.g. dendritic cells, T cells and macrophages). Through these 
interactions, NK cells can therefore fine-tune the scale of the immune responses (1).  
 
1.2 Nasal-type Natural killer/T-cell lymphoma (NKTL) 
Nasal-type natural killer/T-cell lymphoma (NKTL) is a rare cancer of the NK and NK-T cells 
(2). It is an aggressive lymphoma marked by extensive necrosis and angioinvasion, most often 
present in the extranodal sites, in particular the nasal or paranasal sinus region.  It is a distinct 
clinicopathological entity most commonly affecting Asians and Central/South Americans, and 
characterized by a clonal proliferation of NK or NK-T cells. The occurrence of NKTL is strongly 
associated with the geographical distribution of Epstein-Barr virus (EBV) infection (3), 
suggesting EBV infection is a cause for the development of this disease. Recent studies have 
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accumulated understanding of the NK cell biology, causes of malignant transformation and 
prognosis. Rarity and heterogeneity of the disease makes this cancer difficult to manage. 
Insufficient supply of tumor samples also limits development of intense research in this field. In 
addition, aggressive behaviour and poor response to chemotherapy makes it important to search 
for novel therapeutic targets. The 5-year survival rate is less than 50%, in absence of effective 
treatment; the median survival for advanced stage disease is only 6-12 months (4) (Figure 1.1). 
 
 
Figure 1.1 Overall survival rate and progression-free survival of NK/T-cell lymphoma. 
[Source: Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of 
Waldeyer Ring. Blood. 2008 Oct 15;112(8):3057-64] 
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There is no consensus on the standard treatment regime of NKTL; because of the lack of 
randomized clinical trials due to the low incidence of this cancer. In early stage NKTL, it is 
usually managed with chemotherapy and radiotherapy. In stage I/II nasal-type NKTL, 
radiotherapy is an important mode of treatment. The response rate of localized nasal disease after 
radiotherapy ranged from 60%-80%, with a complete remission (CR) rate of 40%-80% and a 5-
year overall survival (OS) of 40-59% (3).  However, despite the good initial response to 
radiotherapy treatment, a high relapse rate (~50%) is reported.  Due to the high relapse rate with 
single radiotherapy therapy, combination of chemotherapy-radiotherapy is the current standard 
of care in patients.  
For stage III/IV nasal-type NKTL, chemotherapy is the primary treatment (3). The overall 
response rate is ~ 67% with a CR rate of ~50%. Allogeneic hematopoietic stem cells (HSCs) 
transplantation is also considered for suitable candidates. Allogeneic HSC transplantation 
harbours the potential benefit of graft-versus-lymphoma (GVL) effect, and thus is a sound option 
for patients with advanced NKTL. The GVL effect is further enhanced by the expression of 
Epstein-Barr virus antigen on tumor cells, providing an alloreactive target. Small-scale studies 
have shown that it is a potentially curative option. On the other hand, the potential benefits of 
HSC transplantation in stage I/II NKTL patients is questionable, since they are expected to 
respond to the radiotherapy/chemotherapy regime (5). 
Despite the current therapies used to manage NKTL, there are high chances of relapse in early 
stages and high mortality associated with advanced stages. Thus, there is still a pressing need to 
discover novel means to treat this cancer. 
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Recently, my group and others have performed gene expression profiling (GEP) studies to 
identify genes and pathways that are activated in the NKTL cells. Not surprisingly, several well-
known oncogenic pathways have been identified, including  AKT, STAT3, NF-kB, c-MYC,  and 
the tumor suppressor gene, p53, is also found to be deregulated in NKTL. In one of our 
published study performing whole genome GEP on extranodal nasal-type NKTL cells (6), we 
also found that a novel gene, Ezh2, may be an interesting target in NKTL cells. These identified 
genes may be potential targets for therapy and thus worth exploring.  
 
1.3 Ezh2 in NKTL 
1.3.1 Histone methylation in cancer 
Histone methylation plays an important role in transcriptional regulation. DNA is wrapped 
around proteins called histones (H2A, H2B, H3 and H4) into structures called nucleosomes, 
which is further compacted using H1 and other non-histone proteins (7). This units of 
nucleosomes come together to form the chromosome, and is further coiled into a shorter and 
thicker structure which is the chromatin. Since the DNA is packaged into such a compact, 
higher-order structure, the genes are inaccessible by RNA polymerases during the process of 
transcription. Thus, it is important that the chromatin structure is able to “open up” during 
transcription, and this is made possible by histone methylation.  
Histones can be reversibly modified through the addition of ubiquitin, acetyl, methyl, or 
phosphate groups onto the histone tail (Figure 1.2) (8-9). When the histone tails are modified, 
they are recognized by other effector proteins, which results in two consequences: activation or 
repression of the gene. The enzymes responsible for adding modifications to histone tails is also 
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a hot topic for investigation, and many of them has been identified and characterized int he 
recent years.  
Methylation of lysine residues can occur on H3 (K4, K9 and K27) or H4 (K20). The 
methyltransferases contain a conserved catalytic domain, the SET domain, and it has been shown 
that deletion of the SET domain is able to abolish the methyltransferase activity of the enzyme 
(10). There are four classes of lysine methyltransferases, SET1, SET2, SUV39 and RIZ family, 
and the classification is based on the similarity of the SET domain (7). Ezh2 belongs to the SET1 
family of lysine methyltransferases.  
 
 
Figure 1.2 Sites and types of the post-translation modifications on histone tails. The type of 
modifications includes phosphorylation, acetylation, methylation and ubiquitination 
[Source: Transcription regulation by histone methylation: interplay between different 
covalent modifications of the core histone tails. Genes & Dev. 2001. 15:2343-2360].  
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1.3.2 Ezh2 and the PRC2 complex in cancer 
The Polycomb Group (PcG) proteins are a group of proteins that are involved in maintaining the 
silenced state of genes. The PcG proteins function in two distinct complexes, the Polycomb 
repressive complex 1 and 2 (PRC1 and PRC2) (11). The PRC2 complex, contains minimally the 
Ezh2, Eed and Suz12 components (12), has lysine methyltransferase activity and trimethylates 
histone 3 lysine 27 (H3K27) (13-15). This modification causes the target gene to be 
transcriptionally repressed and silenced. The PRC2 complex plays an important role in X-
chromosome inactivation and maintenance of stem cell fate, and also shown to be abberantly 






Figure 1.3 Diagram showing the components of the PRC2 complex containing Ezh2, EED 
and SUZ12. The PRC2 complex has methyltransferase activities on histone proteins 
[Source: The Polycomb complex PRC2 and its mark in life. Nature 469, 343–349] 
 
Enhancer of zeste 2 (Ezh2) is the catalytic subunit of PRC2. It contains lysine methyltransferase 
activity within the C-terminal SET domain (16) (Figure 1.4). Ezh2 has been found to be 
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overexpressed in a variety of cancers including prostate, breast, colon, liver and lung cancer, and 
is associated with a more aggressive disease (17-24). Ezh2 has been proposed to have a role in 
cellular proliferation (23), as it was found to be expressed in proliferating, but not resting, mantle 
cell lymphoma cells. When Ezh2 was overexpressed in B cells, it causes an increase in cell 
proliferation, and when Ezh2 is silenced in prostate cells, cell proliferation is inhibited (19-21). 
The levels of Ezh2 in breast cancer also associates with aggressiveness of the disease, causing an 
increase in cell invasion and metastasis (22). Since an intact SET domain is required for cell 
proliferation, it is likely that the normal levels of H3K27 trimethylation is altered on target genes 




Figure 1.4 EZH2 is the catalytic subunit of PRC2 that contains a SET domain. Five 
functional domains are shown in the diagram. The SET domain contains the histone 
methyltransferase active site and the CXC domain contributes to activity. EID domain and 
Domain II allows Ezh2 to interact with the other components of the PRC2 complex for 
robust function of PRC2 [Source: Roles of the EZH2 histone methyltransferase in cancer 
epigenetics. Mutat Res. 2008 Dec 1;647]. 
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1.3.3 Overexpression of Ezh2 in NKTL 
A separate study done by other members of my lab group performed a genome-wide gene 
expression profiling (GEP) of extranodal nasal-type NKTL using formalin-fixed, paraffin-
embedded tissue (FFPE) and NK cell lines in comparison with normal NK cells and normal 
FFPE tissues. We consistently found that Ezh2 transcripts level was significantly higher in 
NKTL compared to normal NK cells as identified by our GEP data and quantitative RT-PCR 
validation  (24) (Figure 1.5).  Whole tissue sections of 36 NKTCL cases were used in this study 
and in addition to GEP, immunohistochemistry (IHC) was performed to further support this 
theory. It was found that of these, 67% of the cases showed positive expression of EZH2 in 
tumor cells as compared to only minimal level of Ezh2 staining in 5% of the normal NK cells 
(Figure 1.6). This data proves that Ezh2 expression was significantly higher in NKTCL when 
compared to normal NK cells at both mRNA as well as protein levels. The selective expression 
of Ezh2 in cancer but not normal NK cells could single Ezh2 out as a potential target for drug-
related therapies.   
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Figure 1.5 EZH2 mRNA levels are elevated in NKTL and cell lines. Diagram showing the 
expression score for EZH2 mRNAs in NKTL gene expression profiling dataset [Source: 
EZH2 overexpression in natural killer /T-cell lymphoma confers growth advantage 
independently of histone methyltransferase activity. Blood March 25, 2013] 
 
Figure 1.6 Representative images of EZH2 immunohistochemical staining in NKTL and 
normal NK cells. The strong staining of EZH2 in NKTL but not normal NK cells. [Source: 
EZH2 overexpression in natural killer /T-cell lymphoma confers growth advantage 
independently of histone methyltransferase activity. Blood March 25, 2013] 
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Furthermore, forced over-expression of Ezh2 in primary NK cells purified from human 
peripheral blood demonstrates that Ezh2 confers a growth advantage in primary NK cells (24). In 
NKTCL tumor cells, a significant positive correlation is observed between the expression of 
Ezh2 and Ki-67 (a marker for cell proliferation). These results and other experiments performed 
in our study show that increased levels of Ezh2 expression provides NK cells with a distinct 
growth advantage (Figure 1.7). This could mean that Ezh2 plays an important role in the 
progression of NKTL.   
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Figure 1.7 EZH2 overexpression in NKTL (NKYS and KHYG cell lines) promotes cell 
growth independent of histone methyltransferase activity [Source: EZH2 overexpression in 
natural killer /T-cell lymphoma confers growth advantage independently of histone 
methyltransferase activity. Blood March 25, 2013].  
 
1.4 3-Deazaneplanocin A (DZNep) 
Deazaneplanocin A is a cyclopentenyl analog of 3-deazaadenosine and originally synthesized to 
inhibit S-adenosyl-L-homosysteine (AdoHcy) hydrolase (25), the enzyme involved in the 
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reversible hydrolysis of AdoHcy to adenosine and homocysteine (Figure 1.8 and 1.9). Inhibition 
of AdoHcy hydrolase causes the accumulation of AdoHcy levels, which leads to inhibition of S-
adonosyl- L-methionine-dependent methyltransferase (MTase) activity (26). Thus, DZNep also 
indirectly inhibits S-adenosyl-methionine (AdoMet)–dependent reactions, making it active 
towards several methyltransferases.   
 
Figure 1.8 DZNep is a cyclopentenyl analog of 3-deazaadenosine, originally synthesized as 
an inhibitor of S-adenosyl-L-homosysteine hydrolase (AdoHcy) [Source: Pharmacologic 
disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces 
apoptosis in cancer cells. Genes Dev. 2007 May 1;21(9):1050-63]. 
 
It has been recently shown to deplete Ezh2 protein, leading to the inhibition of trimethylation of  
H3K27. Through the effects of DZNep on H3K27me3, it reactivates tumor suppressor genes 
(TSG) in cancer cells. DZNep has been shown to cause cell cycle arrest and apoptosis in cancer 
cells as a result of Ezh2 depletion (27). Since DZNep exhibits anti-cancer activities towards a 
broad range of tumors and leukemia, it may be active against NKTL as well. If DZNep is also 
effective at causing cell cycle arrest or apoptosis of NKTL cells, it might be an effective 
  26 
epigenetic agent in combinational therapies or to slow the cancer cell proliferation to allow for 
other treatments to take effect.  
 
 
Figure 1.9 Chemical structure of DZNep [Source: 
https://www.caymanchem.com/app/template/Product.vm/catalog/13828/promo/emolecules]. 
 
1.4.1 DZNep kills AML cells 
Our group also investigated the anti-cancer effects of DZNep on Acute Myeloid Leukemia 
(AML). We looked at a panel of human AML cell lines, and tested the efficiency of DZNep in 
effecting apoptosis (28). Although the cells displayed different sensitivities to DZNep, most of 
the cell lines like Molm-14, MV4-11 and Kasumi-1 showed high levels of cell death when 
exposed to 5uM DZNep (Figure 1.10). We further examine the AML cells from clinical samples 
as well. We also observed significant cell death in primary AML cells, indicating that DZNep 
has anti-leukemic activities in AML (Figure 1.11).  
Colony formation assay (CFU) measures the clonal proliferation of cancer cells. We treated the 
leukemic and normal bone marrow cells with DZNep and counted the colonies. The number of 
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AML-CFU decreased with increasing concentration of DZNep. On the other hand, DZNep had 
little effect on normal bone marrow cells (Figure 1.12). 
To check whether these anti-leukemic effects are also seen in vivo, we conducted bone marrow 
engraftment and subcutaneous implant animal experiments.  2 mg/mL of DZNep reduced tumor 
growth of Molm-14 AML cells, and prolonged survival of NOD/SCID mice with AML (Figure 
1.13). 
 
Figure 1.10 Apoptosis assay by FACS analysis of Annexin-V of DZNep drug treatment on 
different AML cell lines. [Source: The histone methyltransferase inhibitor, DZNep, up-
regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 
2011 Sep 8;118(10):2830-9.] 
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Figure 1.11 Table showing the IC50 values of DZNep in 16 AML patient samples as well as 
several AML cell lines with FAB subtype information [Source: The histone 
methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and 
targets leukemia cells in AML. Blood. 2011 Sep 8;118(10):2830-9.] 
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Figure 1.12 Colony forming units (CFU) were counted in normal hematopoietic stem cells 
(HSCs) versus leukemic stem cells (LSCs) treated with DZNep. Graph is displayed with 
0uM DZNep control as 100%. [Source: The histone methyltransferase inhibitor, DZNep, 
up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 
2011 Sep 8;118(10):2830-9.] 
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Figure 1.13 Mice were treated with either PBS or DZNep and tumor volume was plotted.  
Survival analysis showed that with DZNep treatment, mice with human leukemia has 
improved survival time. Seven mice were used for each group. [Source: The histone 
methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and 
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1.5 Dysregulation of the NF-kB pathway in lymphoma 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) is a protein complex that 
controls DNA transcription with a key role in regulating innate and adaptive immune responses 
towards infections. NF-kB1 and NF-kB2 proteins contains a N-terminal DNA-binding domain 
(DBD) and C-terminal contains a number of ankyrin repeats. They are present as large 
precursors, p105 and p100 respectively, and undergo proteasome degradation of the C-terminal 
to generate the mature forms of NF-kB, p50 and p52 respectively. NF-kB is present in the 
cytosol in an inactive state bound to the inhibitory protein, Nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor, alpha (IkBα). The IkB proteins keep NF-kB 
sequestered in the cytoplasm by masking their nuclear localization signals (NLS) (29). When 
appropriate extracellular signals activates the IkB kinase (IKK), it phosphorylates IkBα and 
targets it for degradation. NF-kB is thus freed and translocates to the nucleus to regulate the 
transcription its target genes (30). One of the target genes of NF-kB is IkBα, which then rapidly 
accumulates and further inhibits NF-kB in a post-induction repression mechanism to inhibit NF-
kB signaling (Figure 1.14) (31). This demonstrates the tight regulation of the NF-kB pathway, 
dysregulation of which will lead to cancer and disease. 
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Figure 1.14 TNF-mediated signaling to NF-kB. TNF binding to TNF-R1 recruits the 
TRADD, which in turn recruits FADD, RIP and TRAF2. RIP and TRAF2 further recruit 
IKKs to activate NF-kB. NF-kB then translocates to nucleus to activate downstream genes 
[Source: A20 inhibits NF-κB activation by dual ubiquitin-editing functions. Trends 
Biochem Sci. 2005 Jan;30(1):1-4.]. 
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NF-κB is abberantly activated in many cancers. NF-kB plays an important role in cancer through 
the regulation of genes involved in cell survival and cell proliferation, and thus is pro-oncogenic. 
Frequently in tumors, NF-kB is found to be constitutively active through mutations encoding the 
NF-kB itself or inactivating mutations in the IκBα proteins, both leading to a constitutive 
signaling of the NF-kB pathway and a malignant phenotype. For example, IκBα inactivating 
mutations are commonly found in lymphomas (32). Amplification, rearrangements, point 
mutation and overexpression of genes encoding NF-kB, notably NF-kB2 is also mostly found in 
lymphomas. Thus, constitutive activation of the NF-kB pathway plays a central role in the 
pathogenesis of lymphomas through mediation of cell proliferation and survival of lymphoma 
cells, and blocking NF-κB have important therapeutic applications in this type of cancer. 
 
1.6 TNFAIP3/A20 tumor suppressor gene in lymphomas 
Tumor Necrosis Factor, alpha induced protein 3 (TNFAIP3) is a cytoplasmic zinc finger protein 
and a negative regulator of NF-kB (33) (Figure 1.15). TNFAIP3 is generally low in most cell 
types, but its expression is rapidly induced upon the activation of NF-kB. TNFAIP3 then 
functions as a negative feedback regulator of NF-kB signaling (34). TNFAIP3’s regulatory 
activity is conferred by its domains: a N-terminal  deubiquitinating enzyme (DUB) activity and a 
C-terminal E3 ubiquitin ligase activity. Receptor Interacting Protein-1 (RIP1) is an essential NF-
kB signaling molecule. TNFAIP3 DUB activity removes the K63-linked polyubiquitin chains 
from RIP1, then the TNFAIP3 E3 ubiquitin ligase activity promotes RIP1 K48-linked 
polyubiquitination, causing the  proteasome-mediated degradation of RIP1.  







Figure 1.15 NF-kB Downregulation by TNFAIP3/A20. The C-terminal domain of 
TNFAIP3/A20, composed of seven C2/C2 zinc fingers, is a ubiquitin ligase that 
polyubiquitinates RIP with K48-linked ubiquitin chains, thus targeting RIP for 
proteasomal degradation [Source: A20 inhibits NF-κB activation by dual ubiquitin-editing 
functions. Trends Biochem Sci. 2005 Jan;30(1):1-4]. 
 
Being the inhibitory factor in the NF-kB signaling pathway, TNFAIP3 is thus recognised as a 
tumor suppressor gene (TSG) in lymphomas, including Hodgkin lymphoma, non-Hodgkin 
lymphoma (mantle cell lymphoma and diffuse large B-cell lymphoma), primary mediastinal B 
cell lymphoma and marginal zone B-cell lymphoma (35-36).  
Recently, multiple reports have revealed that TNFAIP3 is frequently inactivated by mutations or 
deletions in multiple B-cell lymphomas, Hodgkin’s lymphoma, activated B-cell like diffuse large 
B-cell lymphoma and follicular lymphoma, mucosa-associated tissue (MALT) lymphoma (35-
36), and these lymphomas are all frequently associated with abberant activation of the NF-kB 
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signaling pathway. Further experiments have shown that re-introduction of the TNFAIP3 gene 
can induce cell cycle arrest and apoptosis (35), together with the downregulation of NF-kB 
activation. In addition, cells without TNFAIP3 generated tumors, and the tumors were 
suppressed when TNFAIP3 is re-expressed. Thus, TNFAIP3 role in lymphoma as a TSG, whose 
dysregulation might represent a common mechanism leading to constitutive or aberrant NF-kB 
activation, is worth exploring. 
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1.7 Aims of research 
Our group has published articles showing that Ezh2 is commonly overexpressed in NKTL, and 
DZNep selectively kills AML cells. Thus, this study was proposed to ascertain the effectiveness 
of the drug DZNep in targeting Ezh2 and killing in NKTL cells. If proven effective at targeting 
NKTL cells but spares normal NK cells, we will further discover the downstream genes that are 
affected by the inhibition of Ezh2 and the disruption of the PRC2 complex. Since the underlying 
mechanism on how this drug functions is also largely unknown, doing a gene expression 
profiling (GEP) study also aims to increase the understanding on the mechanism of apoptosis 
mediated by DZNep. It is hoped that further understanding of the genes affected by Ezh2 
inhibition will enable us to come up with better forms of targeted therapy to help treat NKTL, or 
combinational therapy to better enhance the effects of current drugs used to treat NKTL. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Cell culture and Plasmids 
The NK tumor cell lines used in this study included the KHYG (NK leukemia cell line, Japanese 
Collection of Research Bioresources), and NKYS (NK lymphoma cell line, a gift from Dr YL 
Kwong). The cells were grown in RPMI containing 10% fetal bovine serum (FBS), penicillin 
(100 U/ml), streptomycin (100 μg/ml) and L-glutamine 2 mmol/L (Sigma - G7513) at a density 
of 5 × 10
5
 cells/ml in 37°C, 10% CO2 incubator and supplemented with 200mg per ml of 
interleukin-2 (IL-2).  The cells were generally passaged three times a week by adding fresh 
medium and resuspending at the appropriate cell density. 
Ezh2 siRNA (#6509) was purchased from Cell Signaling technology, TNFAIP3/A20 siRNAs 
(#7128) were purchased from Origene. TNFAIP3/A20 full-length cDNA was cloned into 
pEGFP-C1 mammalian plasmid. Fusion protein expression was determined by GFP signal.  
 
 
2.2 Drug treatment  
1 million cells in log-phase growth were seeded with 2 mL medium, and treated with 500 nM, 
1uM, 2uM or 5uM of drug DZNep in a 6 well dish. The dish was incubated untouched in 37°C, 
10% CO2 incubator for 48 hours before harvesting for protein or RNA. DMSO drug was used as 
a treatment control.  
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2.3 RNA extraction 
The cells were harvested by washing twice in ice-cold 1X phosphate buffered saline (PBS) and 
cell pellet is collected by centrifuging 1200 rpm for 5 minutes each time. Total RNA was 
extracted using the Trizol Reagent (Invitrogen - 15596-026) and purified with the RNAeasy Mini 
Kit (Qiagen - 74104). Reverse transcription procedure was performed using SuperScript II Kit 
(Invitrogen - 18064-014). Care was taken to prevent DNA contamination and DNA 
contamination was also removed by DNase (Ambion - AM2238) treatment. The RNA was 
further purified by an RNAeasy column (Qiagen - 74104) for a clean preparation. 
 
2.4 Reverse transcription-Quantitative PCR (RT-PCR)  
1ug of good-quality RNA (determined by a nanodrop A260/280 reading of ~2 ) was used as the 
starting material to reverse transcribed into cDNA using the iScript reverse transcription 
supermix (Biorad - 170-8840). Basically, the 5x supermix reagent, RNA template and nuclease-
free water is assembled into a clean PCR tube of a total volume of 20 uL on ice. The reverse 
transcription is performed as per manufacturer's instructions.  
The cDNA is used for real-time PCR. Quantitative PCR analyses were performed in real time 
using an ABI PRISM 7300 sequence detection system and iQ SYBR green supermix (Biorad - 
170-8880). The 2x supermix is thawed on ice and protecting from light. The reaction is 
assembled on ice, containing the cDNA, forward and reverse primers (primer sequences and 
concentrations in section 2.14), and water to a total volume of 20 uL in a 96 well microplate. 
Wells are sealed with a optically transparent film to minimise evaporation. The microplate is 
vortexed, spin down and avoid bubbles in wells. PCR run is setup according to manufacturer's 
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instructions. Each reaction is performed in triplicates and beta-actin is used as the housekeeping 




2.5 Protein extraction 
The cells were harvested by washing twice in ice-cold 1X phosphate buffered saline (PBS) and 
cell pellet is collected by centrifuging 1200 rpm for 5 minutes each time. The cells were lysed 
using RIPA lysis buffer (150 mM sodium chloride, 1.0% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS and 50 mM Tris, pH 8.0). Protease inhibitor cocktail (Pierce 78430) 
and phosphatase inhibitor cocktail (Sigma - p5726) was added to 1x concentration just before 
use. Cells and lysis buffer mix was placed on ice for 30 minutes with mixing. After incubation, 
the protein lysate were spun down at 14,000g for 15 minutes at 4
0
C. The supernatant was 
transferred out into 1.5mL eppendorf tubes and stored at -80
0
C for long-term or -20
0
C for short-
term use.  
 
2.6 Western Blotting 
Appropriate volumes of 1x or 5x Laemmli buffer (4% SDS, 10% 2-mercaptoehtanol, 20% 
glycerol, 0.004% bromophenol blue and 0.125 M Tris HCl, pH 6.8) was added to the protein 
lysate and heated at 95
0
C for 5 minutes. The boiled protein samples were then cooled down on 
ice to room temperature before loading into gel. Proteins are separated on either 10% (for 
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separation of proteins 25-100 kDa) or 16% SDS-PAGE gels (for separation of proteins below 30 
kDa). 1X Running buffer compositions is: 28.8g glycine, 6.04g Tris base, 2g SDS and 1.8L 
ddH2O.  
Equal amount of proteins (as determined using Bradford assays) are loaded on a gel, and beta-
actin acts as the loading control. The gel is run at 100V for about 1 hour or until the loading front 
has reached the bottom of the gel. The molecular weight markers (Biorad) was used used to 
determine whether the protein of interest has separated sufficiently. Generally, 50 ug of protein 
was used for detection of nuclear proteins, and 25 ug of protein was used for the rest of the 
proteins examined. 
The protein separated on gel is then electrophoretically transferred to a polyvinylidene difluoride 
membrane (PVDF) using 100V and 1.5 hours. PVDF membranes require activation by soaking  
in methanol for 1-2 minutes before use. After transfer, the proteins were visualised using 
Ponceau Red (2% Ponceau S in 30% trichloroacetic acid and 30% sulfosalicylic acid). The 
membrane is stained for 5 minutes before removal of stain and washed several times until bands 
can be seen clearly. Membranes were then blocked in 1x phosphate-buffered saline (PBS) with 
5% milk for 1 hour to prevent non-specific background binding. This is followed by three 5 
minute washes using 1x PBS containing 0.1% Tween (PBST). 
After blocking of membrane, it is incubated in primary antibody overnight at 4
0
C. Primary 
antibodies were diluted in appropriate dilutions (1:100-1:5000) using 3% bovine serum albumin 
(BSA) or 3% milk in 1x PBS. The primary antibodies used included beta-actin (Santa Cruz - SC-
47778) EZH2 (Cell signaling - #4905), H3 (Cell signaling - #9715), H3K27me3 (Cell signaling - 
#9756), NFkB p105/p50 (Cell signaling - #3035), EED (Millipore - 09-774) and SUZ12 (Santa 
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Cruz - G-18). The membrane is washed several times in PBST while agitating, 5 minutes per 
wash, to remove residual primary antibody.  
The secondary antibodies (1:5000) is diluted in 3% BSA in 1x PBS. This dilution has been 
optimized to reduce background signal. Secondary antibody incubation is 1 hour at room-
temperature. Antibody – antigen complexes were detected using ECL reagent for HRP-
conjugated antibodies. Western blot images were acquired using a luminescent image analyzer. 
The secondary antibodies used are anti-rabbit (Santa Cruz - SC-2313) and anti-mouse (Santa 
Cruz - SC-2302).  
 
2.7 Apoptosis and Flow cytometry 
Apoptosis was determined through staining cells with Annexin V coupled with FITC 
fluorochrome (BD Pharmingen) and detection using flow cytometry. In early apoptosis, the 
membrane phospholipid phosphatidylserine (PS) is translocated from the inner to the outer 
leaflet of the cell membrane. Annexin V is a protein that binds with high affinity to PS, and thus 
binds to cells with exposed PS. Protocol was performed according to the manufacturer's 
reccomendations. In this study, the 2 NK cell lines, NKYS and KHYG, were incubated with 
various concentrations of the drug DZNep and harvested after 48 hours of treatment. 1 million 
cells were counted and washed with 1xPBS twice. The cells were then incubated with 1X 
Binding Buffer (0.2 μm sterile filtered 0.01M Hepes (pH 7.4), 0.14M NaCl, and 2.5 mM CaCl2 solution) 
at a concentration of 1 x 10
6
 cells/ml, and 100 µl of the solution (1 x 10
5
 cells) was transferred to 
a 15mL falcon tube. 5uL of Annexin V-FITC and 5uL of 50ug/ml propidium iodide (PI) were 
added to the cells, resuspended well by reverse piptetting and incubated in the dark for 15 
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minutes at room temperature. Finally, 400 uL of 1X Binding Buffer was added, and cells were 
kept on ice and in the dark until analysis. Analysis by flow cytometry was always done within an 
hour by FacsCalibur and CellQuest software. Percentage of apoptotic cells was defined by the 
Annexin-V positive gated cells and compared to the total number of cells gated. A minimum of 
100,000 events were collected for each experiment. Non-treated cells was used to gate the 
apoptotic cells. 
 
2.8 Cell proliferation assays  
10,000 cells from 6 different types of malignant NK cell lines ( NK-92, KHYG,  SNT-8, SNK-1, 
SNK-6 and HANK-1) were plated  in a 96-well tissue culture plate with 100uL of medium. After 
growing the cells for 24 hours, the cells were treated with various concentrations of the drug 
DZNep for a period of 48 hours. At the end of the treatment period, 20uL of MTS solution was 
added to each well (Promega) and the absorbance was measured at 490nm using a plate reader. 
Value was an average of 8 readings and experiment was done in triplicates.   Data is presented as 
a percentage of the control cells cultivated under the same conditions without the drug treatment.  
 
2.9 Primary patient sample processing 
Highly purified (90%-99%) untouched normal human NK cells were isolated from whole blood 
samples obtained from healthy donors and buffy coat packs of whole blood samples from the 
Blood Donation Center, National University Hospital, using the NK cell isolation kit (Miltenyi 
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Biotec - 130-92-657). The isolated NK cells were subsequently stimulated by culturing in the 




The amplification kit used to perform microarray was Nugen Applause WT system and the 
labeling kit was Nugen Encore Biotin Module. The GeneChip model was Affymetrix 
HumanGene 1.0ST arrays. Protocols were performed according to manufacturer’s instructions. 
 
2.11 Chromatin immunoprecipitation assay (ChIP) 
Chromatin immunoprecipitations were performed with cross-linked chromatin from 5 x 10
6
 cells 
and incubated with either 10 µl of EZH2 Antibody or 2 µl of Normal Rabbit IgG as negative 
control overnight in the cold room. The DNA-antibody complex is precipitated using 50uL of 
A/G magnetic beads, and subjected to several washes. The precipitated beads were then used for 
de-crosslinking with proteinase K at 65
0
C for 2 hours. The DNA was then purified using the 
Qiagen PCR purification kit, and used for PCR with the respective primers to determine binding 
at the promoter region.  
 
2.12 BrdU proliferation assay 
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NKYS cells were cultured in 96-well plate with R10 supplemented with IL2 and pulse-labeled 
with BrdU (1:100 dilution of concentrated stock) for 4 hours at 37
0
C (Roche - 11647229001). 
Cells were then fixed with 200 µl of FixDenat solution and incubated for 30 min at room 
temperature. The FixDenat solution was removed and 100 µl of Anti-BrdU-POD (75mU) was 
added and the cells incubated for 60 min, RT. After three washes, substrate was added for 
15mins, RT. Absorbance was measured using an ELISA plate reader at 370 nm. 
 
2.13 Transfection 
Transfections for NKTL cells were performed using the Neon (Invitrogen - MPK100025) system 
as recommended by the manufacturers’ protocol. 1.1 million NKYS cells were used per 
transfection. Spin the cells at 900 rpm, room temperature for 3 minutes. Wash once with PBS. 
The Neon machine was optimized and set to 1800V, 10ms pulse width, 1 pulse for transfection. 
Cell pellet was resuspended in Resuspension buffer R (110ul per transfection), and added with 
5.5 ul of a siRNA solution to a single Eppendorf tube. The electroporated cells were released into 
R10 supplemented with IL2 medium on the 6-well plate. Incubate at 37°C with 5% CO2. Cells 
were harvested after 2 days to assess knockdown level. 
2.14 Primers 
All Primers are diluted to the working concentration of 10uM 
Ezh2: Fwd:5′-TACTTGTGGAGCCGCTGAC, Rev:5′-CTGCCACGTCAGATGGTG 
ChIP Primer 1 Forward 5’-CAGCCCGACCCAGAGAGTCAC-3’ Reverse CGGGCTCCAAGCTCGCTT 
ChIP Primer 2 Forward 5’-CAGCCCAAACTTTTCAGAGC-3’ Reverse GGTGATGGGAACTGGAAATG 
TNFAIP3_Forward AGG GGG CGC GCC ATG GCT GAA CAA GTC CTT CCT Reverse GTG GGC GGC CGC 
CGG TTA GCC ATA CAT CTG CTT G 
  45 
SMYD3 Forward CAG GCA ATC ATA AGC AGC AA Reverse TCT TCA TTG CTT GGG GAA AC 
TNIP3 Forward GTG CCT GGT CAT GTT TTC CT Reverse TTT GTG CAT CCA ACA GCA AT 
NFKBIA Forward GCA AAA TCC TGA CCT GGT GT Reverse GCT CGT CCT CTG TGA ACT CC 
CXCLL10 Forward GGA TGG CTG TCC TAG CTC TG Reverse ATA ACC CCT TGG GAA GAT GG 
UBD Forward CCT TAC CCT GAA GGT GGT GA Reverse CTT CCA GCT TCT TTC CGT TG 
NCAM2Forward GGA TAT AGT GCG GCA AGA GC Reverse CAT GTT CAG GAC GTG ACA CC 
Cyclin D2 Forward; 5′- TGGAGCTGCTGTGCCACG Reverse; 5′- GTGGCCACCATTCTGCGC  
IRF4 Forward; 5′- AGAAGAGCATCTTCCGCAT Reverse; 5′- TGCTCTTGTTCAAAGCGCAC  
BCL-xL Forward; 5′- GGAACAATGCAGCAGCCGAG Reverse; 5′- GTAGAGTGGATGGTCAGTGT  
c-FLIP Forward; 5′- TGGACCTTGTGGTTGAGTTG Reverse; 5′- TTGGATTGCTGCTTGGAGA  
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CHAPTER 3. RESULTS 
3.1 Inhibition of Ezh2 using DZNep induces apoptosis 
3.1.1 Ezh2 is overexpressed in NKTL cells but not normal NK cells 
Previous studies done by members of my lab group on Ezh2 showed that it is overexpressed in 
NKTL cells as compared to normal NK cells. The ectopic expression of Ezh2 in NKTL cells 
resulted in increased cell proliferation, while knockdown of Ezh2 causes growth inhibition, 
showing that Ezh2 is oncogenic in NKTL disease model. To determine the basal expression of 
Ezh2 in NKTL cell lines, we performed Western Blot of protein lysates from several established 
NKTL cell lines as well as a normal NK protein sample. As shown in Figure 3.1.1, Ezh2 protein 
levels is significantly higher in the NKTL cell lines, while normal NK cells showed very low 
expression of Ezh2. This suggest that Ezh2 is abnormally expressed in NKTL cells. Actin blot 






Figure 3.1.1 Levels of Ezh2 in different NKTL cell lines compared to normal NK cells. 25ug 
of whole cell lysate was used for gel electrophoresis. β-actin showed equal loading across 
protein samples.
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3.1.2 DZNep treatment inhibits Ezh2 protein levels 
S-adenosylhomocysteine hydrolase inhibitor 3-deazaneplanocin A (DZNep) is a global histone 
methylation inhibitor and shown to deplete Ezh2 levels to inhibit trimethylation of histone 3 
lysine 27 (H3K27me3) in cells. Our group has also shown the effectiveness of DZNep in 
inhibition of Ezh2 levels in acute myeloid leukemia (AML) and multiple myeloma (MM). Since 
one of my project aims is to discover downstream genes that are affected by the inhibition of 
Ezh2, we first examine the concentration of DZNep needed to sufficiently inhibit Ezh2 in our 
cell line models. In both KHYG and NKYS cells, we can see a 50% reduction in Ezh2 proteins 
when 2uM or 5uM of DZNep is used to treat the cells (Figure 3.1.2). We also look at the 
H3K27me3 levels, and also start to observe a inhibition when 5uM of drug is used. Histone 3 
levels was used as the loading control for H3K27me3 (Figure 3.1.3).  
 
Figure 3.1.2 Western blot of KHYG and NKYS cells treated with DZNep. KHYG and 
NKYS cells were treated with increasing concentrations of DZNep for 48 hours before protein 
extraction.  25ug of protein was loaded, and β-actin showed equal loading across protein 
samples. 
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Figure 3.1.3 Western blot of KHYG and NKYS cells treated with DZNep. KHYG and 
NKYS cells were treated with increasing concentrations of DZNep for 48 hours before protein 
extraction.  50ug of protein was loaded to probe the levels of H3K27me3, and Histone H3 
showed equal loading across protein samples. 
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 3.1.3 Treatment of NKTL cells with DZNep induces apoptosis in a dose-dependent 
manner 
Next step of the project was to ensure that the DZNep does indeed preferentially induce 
apoptosis in NK cancer cells after Ezh2 inhibition. As such, we used the same concentration 
range tested in Figure 3.1.2 of DZNep on KHYG and NKYS cells. Flow cytometry apoptosis 
assay was performed to test cell viability before and after drug treatment after treating cells for 
48 hours. As can be seen in Figure 3.1.4, the apoptosis assay showed an increase in cell 
apoptosis as the concentrations of the drug DZNep is increased, showing a dose-dependent 
killing of cells. In Figure 3.1.4, increase in apoptosis is seen by an increase in the number of 
cells that have been double-stained with Annexin V-APC and Propidium Iodide (PI). For 
KHYG, cell viability drops from almost 75% (no treatment) to 24% (10uM DZNep). For NKYS, 
cell viability drops from almost 80% (no treatment) to less than 50% (10uM DZNep) viability. 
This graph is a representation of at least 3 repeats of the apoptosis assay. 
To further confirm this, cell proliferation assay of six NKTL cell lines and one normal NK cells 







  50 
 
Figure 3.1.4 Graph showing decrease in KHYG and NKYS cell viability as DZNep 
concentration increases. Cells were treated for 48 hours before analyzing apoptotic markers 












  51 
 
Figure 3.1.5 BrdU assay showing the cell viability of several NKTL cell lines treated with 
increasing concentration of DZNep. NKTL cells were grown in 96-well plate overnight before 
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initiating the treatment with DZNep at the stated concentrations. Viability was determined using 
BrdU assay 48 hrs after treatment according to manufacturer’s instructions. 
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3.1.4 DZNep spares normal human NK cells 
For any drug to be used in clinical treatment however, it must be able to kill only the cancer cells 
while not causing too much damage or harm to the normal NK cells. To prove this, normal 
human NK cells were isolated from the buffy coat of healthy individuals, and treated with 
DZNep at same concentration and duration used to treat the NKTL cells. The blots show that 
even at 10uM of DZNep, there is no visible change in the expression levels of EZH2 in the 
normal human NK cells (Figure 3.1.6). An apoptosis assay was also performed on the drug-
treated normal NK cells to show that the drug does not trigger apoptosis in normal NK cells. The 
apoptosis assay in Figure 4 shows that there is no significant decrease in normal NK cell viability 
when exposed to up to 10uM of DZNep. Although the cells show some decrease in viability, the 
viability only drops from 78% to 68% (Figure 3.1.7) as compared to a much higher death rate in 
the NK cell lines. This shows that targeting Ezh2 might show specificity towards NKTL but not 
normal NK cells. Combination therapies can significantly reduce the amount of drug needed to 
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Figure 3.1.6 Treatment of normal NK cells with DZNep. Western Blot showing that the levels 
of Ezh2 (upper panel) is not affected by increasing concentration of DZNep treatment in normal 
NK cells. Actin (lower panel) is the loading control. 
 
Figure 3.1.7 Treatment of normal NK cells with DZNep. Graph showing the viability of 
normal NK cells is not affected by increasing concentrations of DZNep. Cells were between 70-
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3.2 Ezh2 inhibition increases TNFAIP3/A20 levels 
3.2.1 Gene expression profiling (GEP) on DZNep-treated KHYG and NKYS cell lines 
After we show that DZNep causes apoptosis in NKTL cell lines NKYS and KHYG, we did a 
gene expression profiling (GEP) to determine which genes are up- and down-regulated after 
Ezh2 inhibition. We use 5uM to treat the NKYS cells, and 2uM to treat the KHYG cells. These 
DZNep concentrations used to treat the cells are IC50 values and also show a 50% inhibition of 
Ezh2 protein levels. After treating the cells for 48h, the mRNA was extracted, and a GEP was 
performed on treated vs untreated cells for each cell line. 
A list of genes that were commonly up- or down-regulated by at least two-fold in both cell lines 
was compiled (Table 1). In that list, there were changes in expression levels of several genes that 
were involved in the regulation of the NF-kB pathway. We were interested in the NF-kB 
pathway, because it has been found to be constitutively activated in tumorigenesis of 
hematological malignancies.   
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Table 1 GEP analysis of NKYS cells treated with DZNep. IC50 value of DZNep was used to 
treat the NKYS cells, and a GEP analysis of top genes affected by DZNep treatment was shown 
in the table. The gene name, fold-change and trend of regulation (up- or down-regulation) was 
shown.  
  57 
3.2.2 RT-PCR validation of candidate genes 
To validate the microarray data, we designed primers specific to some interesting genes and 
performed RT-PCT on these genes. The RT-PCR results all concurred with the GEP data and 
showed an increase in the genes TNFAIP3, TNIP3 and NFKBIA, all of which are involved in the 
regulation of NK-kB pathway (Figure 3.2.1). We also examine two genes that were down-
regulated in the microarray data, SMYD3 and NCAM2. Our RT-PCR results also confirmed their 
down-regulation in the NKTL cell lines treated with DZNep (Figure 3.2.2). The RT-PCR results 
are summarized in Table 2. I decided to focus on one of the up-regulated genes, TNFAIP3 to do 
functional experiments to determine its role downstream of Ezh2 in NKTL cell lines.  
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Figure 3.2.1 Validation of the up-regulated genes affected by DZNep treatment in NKYS 
and KHYG cells by RT-PCR. DMSO was used as a treatment control. Housekeeping gene, 
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Figure 3.2.2 Validation of the down-regulated genes affected by DZNep treatment in NKYS 
and KHYG cells by RT-PCR. DMSO was used as a treatment control. Housekeeping gene, 
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Table 2 A summary of the RT-PCR values of genes that were validated. The RT-PCR data 
was in agreement with the GEP data. 
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3.2.3 TNFAIP3/A20 protein is induced by DZNep 
To confirm that the mRNA and protein levels of TNFAIP3 is induced by DZNep, we performed 
RT-PCR and Western Blot of TNFAIP3 levels upon treated with the varying concentrations of 
DZNep. Our results showed a correlation between increase in TNFAIP3 levels with increasing 
concentration of DZNep used (Figure 3.2.3), confirming the fact that TNFAIP3 is up-regulated 






Figure 3.2.3 Treatment with DZNep induces TNFAIP2/A20. RT-PCR and Western blot 
showing the levels of TNFAIP3/A20 during treatment with increasing concentration of DZNep 
as compared to DMSO control. Actin is used as a loading control. (*p < 0.05, **p<0.01)
* 
** 
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 3.2.4 Ezh2 knockdown also increases TNFAIP3/A20 levels 
Since DZNep is an inhibitor of Ezh2, we next examine whether knockdown of Ezh2 can 
similarly induce TNFAIP3 levels. We knockdown Ezh2 in NKYS cells using siRNA transfection 
using the Neon system, and check the mRNA levels of genes. We validated that the levels of 
Ezh2 decreased 50% (Figure 3.2.4), which cause an increase in TNFAIP3 mRNA transcripts 
(Figure 3.2.5). We wanted to perform Western Blot for these proteins as well, however, 
knockdown of Ezh2 was quite lethal to cells, and we could not obtain enough cell numbers to 
examine the protein levels. 
 
Figure 3.2.4 Efficient knockdown of Ezh2 with Ezh2 siRNA. RT-PCR showing the levels of 
Ezh2 after transfection with either control siRNA or Ezh2 siRNA for 48 hrs to determine 
efficiency of knockdown. Actin is used as loading control. (*p < 0.05) 
* 
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Figure 3.2.5 Knockdown of Ezh2 increases TNFAIP3/A20. RT-PCR analyzing the levels of 
TNFAIP3/A20 after transfection with either control siRNA or Ezh2 siRNA for 48hrs. Actin is 
used as loading control. 
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3.2.5 Ezh2 overexpression reduces TNFAIP3/A20 levels 
To further corroborate the fact that Ezh2 negatively regulates TNFAIP3, we also overexpress 
Ezh2 in NKYS and KHYG cells. As expected, transfection of Ezh2 overexpression plasmids 
increased Ezh2 levels, and reduced levels of TNFAIP3 (Figure 3.2.6). Thus, Ezh2 and TNFAIP3 
levels are inversely correlated in NKTL cells. 
 
 
Figure 3.2.6 Overexpression of Ezh2 in NKYS cells. RT-PCR showing the levels of Ezh2 or 
TNFAIP3/A20 after transfection with Ezh2 overexpressing plasmids for 48hrs. Duplicate 
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3.3 Functional relevance of TNFAIP3/A20  
3.3.1 Overexpression of TNFAIP3/A20 triggers apoptosis 
We hypothesize that up-regulation of TNFAIP3 in DZNep treated cells could be a mechanism of 
apoptosis in NKTL cells. TNFAIP3 is a negative regulator of the NF-kB pathway, where 
constitutive aberrant activation of NF-kB has been detected and play a key role in various 
lymphoid malignancies. TNFAIP3 is also identified as a tumour suppressor gene (TSG) in 
several types of lymphoma. In one study of TNFAIP3 in non-Hodgkin’s lymphoma, over-
expression of TNFAIP3 is shown to induce apoptosis and silencing of the gene is shown to 
induce resistance to apoptosis (21). The reintroduction of wild-type TNFAIP3 into TNFAIP3-
deficient non-Hodgkin’s lymphoma cell lines has also been shown to induce apoptosis. 
To look at whether overexpression of TNFAIP3 alone is able to induce apoptosis without Ezh2 
inhibition, we introduce the TNFAIP3 expression plasmid into NKYS cells (Figure 3.3.1). As 
compared to NKYS cells transfected with the control plasmid, overexpression of TNFAIP3 
causes a significant increase of 50% in apoptosis (Figure 3.3.2). This suggests that activation of 
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Figure 3.3.1 Western blot showing the increase in TNFAIP3/A20 levels after transfection 
with TNFAIP3/A20 plasmid. NKYS cells were transfected with TNFAIP3/A20 expression 
plasmid for 48hrs. Cells were harvested for whole cell lysate and probed with TNFAIP3/A20 
antibodies. Actin is used as loading control. 
 
Figure 3.3.2 Transfection of TNFAIP3/A20 plasmid increases apoptosis of cells. NKYS cells 
were transfected with TNFAIP3/A20 expression plasmid for 48hrs, followed by staining with 
Annexin V and PI for apoptosis assay by flow cytometry. (**p<0.01) 
** 
  67 
3.3.2 Knockdown of TNFAIP3/A20 causes resistance to apoptosis after treatment 
with DZNep 
As a more direct way of showing that TNFAIP3 is involved in apoptosis, we knockdown 
TNFAIP3 in NKYS cells, and look at cell proliferation and cell viability in response to DZNep 
drug treatment. Using the Neon Transfection system, the cells were pulsed once at 1800V and 
100pMol of siRNA was used. The cells were harvested after 48 hours after transfection. Two 
independent siRNA targeting TNFAIP3 was used (siRNA 1 and siRNA 2), and the knockdown 
efficiency was determine using RT-PCR as compared to scrambled (SCR) (Figure 3.3.3). 
Western Blot of the knockdown effects was also shown in Figure 3.3.4. After the knockdown 
was successful, the drug DZNep was used to treat the TNFAIP3 knockdown cell lines. DZNep 
was added to the cell lines after 48 hours to give the siRNA time to take effect. We looked at 
MTS and BrdU assays in NKYS cells to determine the effects on cell proliferation. As shown in 
Figure 3.3.5 and Figure 3.3.6, cells showed increase in cell proliferation in both assays when 
transfected with TNFAIP3 siRNA as compared to SCR after treatment with DZNep. Figure 
3.3.7 shows that apoptosis also decreased during DZNep treatment when TNFAIP3 is 
knockdown. Figure 3.3.8 showed the changes in mRNA and protein levels of TNFAIP3 during 
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Figure 3.3.3 Knockdown of TNFAIP3/A20 in NKYS cells. RT-PCR showing the efficiency of 
TNFAIP3/A20 knockdown in NKYS cells with two different siRNA plasmids. Scrambled 
siRNA is used as control for transfection and actin is used as loading control. 
 
Figure 3.3.4 Knockdown of TNFAIP3/A20 in NKYS cells. Western blot showing that 
TNFAIP3/A20 protein levels is also reduced after knockdown. Scrambled siRNA is used as 
control for transfection and actin is used as loading control. 
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Figure 3.3.5 Cell proliferation of NKYS cells with TNFAIP3/A20 knockdown and DZNep 
treatment. MTS assay is used to determine cell proliferation of NKYS cells transfected with 
TNFAIP3/A20 siRNA for 24hrs and then treated with DZNep for 48hrs. Scrambled siRNA is 
used as control for transfection and DMSO is used as control for drug treatment. 
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Figure 3.3.6 BrdU assay is used to determine cell proliferation of NKYS cells transfected 
with TNFAIP3/A20 siRNA and then treated with DZNep. Scrambled siRNA is used as 
control for transfection and DMSO is used as control for drug treatment. 
 
 
Figure 3.3.7 Cell viability of NKYS cells transfected with TNFAIP3/A20 siRNA or 
scrambled control and then treated with DZNep. Cell viability was examined using apoptosis 
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Figure 3.3.8 RT-PCR and Western blot of transfected with TNFAIP3/A20 siRNA or 
scrambled control and then treated with DZNep. The levels of TNFAIP3/A20 changed with 
TNFAIP3/A20 siRNA and treatment with DZNep. Control for drug treatment is DMSO and 
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3.3.3 NF-kB pathway is induced after TNFAIP3/A20 inhibition 
Since TNFAIP3 is a negative regulator of the NK-kB pathway, we check to see whether the NF-
kB p50 protein levels is affected after DZNep treatment. Interestingly, we see a decrease in NF-
kB levels at increasing concentrations of DZNep used, which means it is negatively correlated to 
TNFAIP3 levels (Figure 3.3.9). Next, we check whether the activation of NF-kB could be 
responsible for the resistance to apoptosis observed with TNFAIP3 siRNA knockdown. Our 
Western Blot shows that when TNFAIP3 is reduced, and treated with DZNep, the NF-kB levels 
did not go down (Figure 3.3.10). This can suggest that as compared to controls, the levels of NF-
kB is higher in the TNFAIP3 knockdown cells, and can be responsible for the resistance to 
DZNep. We also looked at several downstream genes of NF-kB, like cyclin D2, Bcl-xL, IRF4 
and c-FLIP. The cells were transfected with scrambled or TNFAIP3 siRNA and treated with 
10uM DZNep. The downstream genes are determined by RT-PCR (Figure 3.3.11). 
 
Figure 3.3.9 DZNep decreases NF-kB levels. Western blot showing the levels of NF-kB p50 
with increasing concentrations of DZNep. Cells were extracted for protein after 48hrs treatment. 
Actin is the loading control and DMSO is control for drug treatment. 
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Figure 3.3.10 Knockdown of TNFAIP3/A20 and treatment with DZNep. Western blot 
showing the levels of NF-kB p50 in NKYS cells transfected with scrambled siRNA control or 
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Figure 3.3.11 Knockdown of TNFAIP3/A20 and effects on downstream genes. RT-PCR 
showing the downstream NF-kB genes, including cyclin D2, Bcl-xL, IRF4 and c-FLIP levels, 
when transfected with scrambled control or TNFAIP3/A20 siRNA. Actin is the loading control 
for RT-PCR. (*p<0.05)
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3.4 Ezh2 regulates TNFAIP3/A20 through H3K27 trimethylation 
3.4.1 Treatment of NKYS with DZNep decreases Ezh2 on TNFAIP3/A20 promoter 
As previously shown in the Western Blots in Figure 3.1.2 and Figure 3.1.3, the levels of total 
Ezh2 and H3K27me3 decreases when increasing concentrations of DZNep is used. Next, we 
want to check whether the decrease in Ezh2 causes a decrease in H3K27me3 on TNFAIP3 
promoter, therefore the levels of TNFAIP3 will increase. This is because H3K27me3 is a 
repressive histone mark. We perform chromatin immunoprecipitation (ChIP) experiments on 
NKYS cells that were treated with DZNep, and PCR with two sets of TNFAIP3 primers.  
Like what we expected, the signal of Ezh2 on TNFAIP3 gene decreases when increasing DZNep 
is used, and is consistent with both sets of primers used (Figure 3.4.1). Especially at the 
concentrations 5uM and 10uM, very little Ezh2 signal is left on TNFAIP3. This could explain 
why the level of TNFAIP3 is markedly increased when 5uM or 10uM of DZNep is used (Figure 
3.2.3).  
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Figure 3.4.1 ChIP-qPCR for endogenous EZH2 binding to the promoter region of  
TNFAIP3/A20 gene. ChIP assays were performed by using NKYS and two primer pairs 
amplifying the promoter region of TNFAIP3/A20. Real-time PCR was performed with 
immunoprecipitated chromatin fragments obtained by using anti-EZH2 antibody or an rabbit 
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3.4.2 Levels of H3K27 trimethylation on TNFAIP3/A20 promoter reduced after DZNep 
treatment 
Next, we determine whether decrease of Ezh2 signal on TNFAIP3 has any effect on the 
H3K27me3 signal it is known to regulate. We saw a similar pattern of H3K27me3 on TNFAIP3 
as the pattern of Ezh2, suggesting that lesser Ezh2 correlates with lesser H3K27me3 (Figure 
3.4.2). This directly shows a mechanism of how Ezh2 regulates TNFAIP3, through its histone 
methyltransferase activity.  
 
 
Figure 3.4.2 ChIP-qPCR for endogenous H3K27me3 binding to the promoter region of 
TNFAIP3/A20 gene. ChIP assays were performed by using NKYS and two primer pairs 
amplifying the promoter region of TNFAIP3/A20. Real-time PCR was performed with 
immunoprecipitated chromatin fragments obtained by using anti-H3K27me3 antibody or an 
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CHAPTER 4. DISCUSSIONS 
Chromatin modifications regulate gene expression in a spatial and temporal manner, and 
therefore dysregulation often lead to diseases such as cancer. For example, DNA 
hypermethylation of gene promoter regions can be associated with a loss-of-function of the gene. 
This is commonly seen in tumor suppressor genes which are silenced through this mechanism. In 
conjunction, the development of drugs targeting this class of enzymes may have great therapeutic 
applications. To date, three drugs have been approved by the FDA for the treatment of cancer. 
Vorinostat, also known as Suberoylanilide hydroxamic acid, is a compound that inhibits histone 
deacetylases (HDACs), is currently used for the treatment of  cutaneous T cell lymphoma 
(CTCL). Decitabine (5-aza-2'-deoxycytidine) and Azacitidine (5-azacytidine), both targeting 
DNA methylation, are used in the treatment of myelodysplastic syndrome and acute myeloid 
leukemia. This suggests that drugs targeting epigenetic pathways are useful in hematological 
malignancies, and this area can be further investigated. 
 
In addition to DNA methylation and histone acetylation, another interesting class of epigenetic 
modifiers are those involved in the histone methylation process. The well-known enzyme 
belonging to this group is the Polycomb repressor complex 2, which consist of the 
methyltransferase component, Ezh2, and two other proteins, EED and SUZ12. Ezh2 is 
responsible for the trimethylation of the histone H3K27, which is a repressive mark causing a 
downregulation of the associated gene. Overexpression of Ezh2 has been associated with 
numerous cancers, including breast, prostate, melanoma and lymphoma (19-24), making it an 
attractive epigenetic target. DZNep was found to selectively inhibit H3K27me3, as well as 
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H4K20me3, through a relatively specific targeting of Ezh2. This drug treatment results in the 
apoptosis of cancer cells (24). 
In this current study, we characterized the anti-cancer effect of DZNep against NKTL in vitro. 
First, we determined the expression level of Ezh2 in NKTL cells, and found that Ezh2 transcript 
levels are frequently overexpressed as revealed by GEP data done in our lab. Our IHC data also 
supports our GEP data showing the increase in protein levels of Ezh2 in NKTL cells as opposed 
to normal NK cells (24). In agreement with the expression levels of Ezh2 in NKTL cells, we 
found that DZNep treatment, which inhibits Ezh2 and H3K27 trimethylation, selectively kills 
NKTL cells but not normal NK cells. We therefore showed that DZNep has a differential effect 
on cancer cells compared with normal NK cells. Importantly, overexpression of Ezh2 confers 
proliferative advantage in NKTL cells, which is a characteristic of cancer cells (24). This 
suggests that Ezh2 is a candidate oncogene in NKTL and inhibition of Ezh2 would be possible as 
a therapy option. Our current study thus reveals a novel way of treating NKTL cells, through 
targeting Ezh2 using DZNep in hematological malignancies. DZNep was previously reported to 
also inhibit H4K20 trimethylation (25), and our group has also published that DZNep inhibited 
global methylation in a non-selective manner in multiple myeloma (MM) cells. Although our 
current study did not analyze other histone modifications, we conclude that NKTL-cell apoptosis 
by DZNep is mediated mainly through depletion of Ezh2 and H3K27 trimethylation inhibition.  
 
To gain insights into the determinants of DZNep-induced apoptosis, we performed a microarray 
study of NKTL cells treated with DZNep at IC50 compared to control that was treated with 
DMSO. Interestingly, we found that many genes involved in the NF-kB pathway to be enriched 
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in our dataset. NF-kB pathway has a well-known role in promoting tumor formation, and is 
found to be constitutively activated in the development of lymphoid-, myeloid- and epithelial-
derived malignancies. It is involved in the deregulation of important hallmarks of cancer such as 
apoptosis, proliferation and inflammation (37-38). The reason we chose to study on candidate 
genes involved in the NF-kB pathway in DZNep-treated NKTL cells is due to the established 
role in lymphoid cancers. The NFKB2 locus on the q-arm of chromosome 10 is frequently 
subjected to chromosomal rearrangements in several lymphomas (38). Despite different 
molecular alterations, they all result in the deletion of the C-terminal domain IkB-like sequences 
and the constitutive synthesis of NF-kB protein, p52. On the other hand, no chromosomal 
rearrangements were seen with the locus containing NFKB1 on chromosome 4, but BCL3, an IkB 
family member, was overexpressed and interacts with NF-kB p50 or p52 to activates 
transcription. These data all point to the fact that NF-kB pathway is important in lymphoid 
cancer and is therefore a target for dysregulation during cancer progression. However, the 
mechanisms conferring NF-kB activation remains unclear. From our data, we suggest that NF-
kB is a downstream molecule of Ezh2. Through figuring out the link between Ezh2 and NF-kB, 
we will unravel the mechanism of how NF-kB is activated in NKTL cells and possibly other 
cancers.  
 
In this study, another aim is to find a direct link of how inhibition of Ezh2 leads to the changes in 
expression levels of the NF-kB pathway molecules, subsequently leading to an anti-cancer effect. 
Our GEP data showed that in DZNep-treated cells, there is an upregulation of TNFAIP3/A20 
and NFKBIA, members of the NF-kB inhibitor family. With the upregulation of these NF-kB 
inhibitory molecules in DZNep-treated cells, this can be a possible explanation for  an inhibition 
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of the NF-kB pathway. The gene that we chose to focus on from the dataset is TNFAIP3/A20. 
This gene is encoded on chromosome 6q, which is frequently deleted in lymphomas, suggesting 
that it is an important tumor suppressor gene that result in proliferative or survival advantage to 
cancer cells upon its loss (36). Our observation in an increase in TNFAIP3/A20 levels coupled 
with a decrease in NF-kB has also been observed by other groups. It was described that 
TNFAIP3/A20 inhibits NF-kB through RIP. TNFAIP3/A20 modify the ubiquitin profile of RIP 
through a two-step process: disassembly of ubiquitin chains from lysine 63 followed by 
ubiquitination at lysine 48. This then targets RIP for proteasomal degradation, terminating the 
NF-kB signaling (33). 
 
Interestingly, we found that TNFAIP3/A20 increase more than two-fold in NKTL cells treated 
with DZNep from the dataset, and we independently confirmed the upregulation at both the 
mRNA and protein levels (Figure 3.2.3). One disadvantage of using of drugs at high 
concentrations is the non-specificity. Therefore, to show more convincingly, we also specifically 
knockdown Ezh2 using siRNA, and showed that it also increases TNFAIP3/A20 levels (Figure 
3.2.5). This suggest that the effect on TNFAIP3/A20 upon DZNep treatment is mainly mediated 
through EZH2 inhibition, and that TNFAIP3/A20 is a true target of Ezh2. Conversely, when we 
overexpress Ezh2, TNFAIP3/A20 expression is attenuated (Figure 3.2.6). This suggest that in 
cells acquiring high Ezh2 levels, TNFAIP3/A20 function as a tumor suppressor is abrogated, 
predisposing cells to oncogenesis. 
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On a separate note, another paper published by our group was also looking at the effects of 
DZNep on AML cells (28). We demonstrated that DZNep effectively induces apoptosis in AML 
cells, and through gene expression profiling, we identified that TXNIP was the primary target. 
We found that TXNIP was repressed in AML cells through occupancy of PRC2 complex on its 
promoter, and can be reactivated upon treating cells with DZNep or Ezh2 inhibition causes 
apoptosis. 
 
We further show that overexpression of TNFAIP3/A20 is sufficient to trigger apoptosis (Figure 
3.3.2). On the other hand, knockdown of TNFAIP3/A20 confers resistance of cells to DZNep 
treatment (Figure 3.3.7). This demonstrates that the upregulation of TNFAIP3/A20 and the 
subsequent attenuation of the NF-KB pathway is a critical event in inducing apoptosis in 
DZNep-treated cells.  
 
 Although TNFAIP3/A20 is commonly inactivated in lymphomas, the mechanism of inactivation 
is less studied. Since Ezh2 is a histone methyltransferase containing the SET domain that allows 
it to add methyl groups to substrates, we examine whether Ezh2 directly inhibit TNFAIP3/A20 
through the direct activities of the histone methyltransferase and the SET domain. Upon DZNep 
treatment, Ezh2 on TNFAIP3/A20 promoter is reduced, resulting in a reduction in H3K27 
trimethylation and de-repression of TNFAIP3/A20 (Figure 3.4.2). In the process, we uncover 
novel regulation of NF-KB signaling by Ezh2 through an histone methyltransferase dependent 
mechanism through effect on the expression of a key inhibitor of the pathway, TNFAIP3/A20. 
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On the other hand, Ezh2 has also been reported to exert oncogenic activities independent of the 
methyltransferase activity in NKTL cells (24). It was discovered that Ezh2 lacking the SET 
domain was able to confer growth advantage to NKTL cells as with the wild-type Ezh2. The 
authors further examine the ability of Ezh2 to regulate the transcription of cell-cycle genes like 
Cyclin D1, and also found that Ezh2 with SET domain deletion was able to bind and activate 
Cyclin D1 promoter region. Therefore, it is without doubt that Ezh2 is an important oncogenic 
molecule in cancer development. Through its direct histone methyltransferase activities or 
through other mechanisms independent of the SET domain, Ezh2 is able to control genes that 
lead to cancer progression. This can be seen through our study where Ezh2 silence a tumor 
suppressor gene like TNFAIP3/A20 through increase in H3K27me3, or through regulating the 
expression of genes involved in cell-cycle by other rmechanisms.  
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CHAPTER 5. CONCLUSIONS 
To conclude, through our study, we have shown that Ezh2 levels are higher in NKTL cells and 
confers proliferative advantage. DZNep targets Ezh2 and induces apoptosis in leukemic cells. 
Thus, we examine the use of DZNep in NKTL cells, and found that it targets NTKC cells but 
spares normal NK cells. We identify the mechanism by which DZNep induces apoptosis in the 
NKTL cells through the upregulation of TNFAIP3/A20 tumor suppressor gene, which results in 
the downregulation of NF-kB. We uncover a novel mechanism by which EZH2 regulate the 
NFKB pathway through its histone methyltransferase activity on promoter of TNFAIP3/A20.  
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CHAPTER 6. FUTURE STUDIES 
There were several other interesting targets identified in the microarray that was not studied in 
this project. For example, it is worth exploring whether TNIP3 or NFKBIA, which were found to 
be upregulated by DZNep treatment and validated independently using RT-PCR, were 
functionally important in the initiation of apoptosis of the NKYS cells by DZNep. By studying 
all the genes in concert, we may have a better picture of how DZNep works mechanistically, and 
know exactly which genes to target in the pathway to exert the same killing effect on the 
cancerous cells. 
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